The one into two at 10
January 2013 brought a clear safety and dose signal in the BI-505 Phase I for relapsed and refractory multiple myeloma (MM). In preclinical studies, BI-505 showed a tumour cell killing effect possibly by making myeloma cells susceptible to apoptosis. The Phase I was dose escalating with a safety end point. Interestingly but anecdotally, seven of 29 patients (24%) on extended dosing showed stable disease. BI-505 will progress to a small Phase IIa during 2013. BioInvent (BINV.ST) intends to partner BI-505
The one: BI-505 is crucial to current value
BI-505 is the remaining clinical programme from the January 2012 portfolio. Hence, gaining maximum value is important for investors. A deal by GenMab in August 2012 with J&J on a Phase I MM antibody, daratumumab, shows possible value. GenMab, a larger company, gained $55m upfront and $88m in equity with milestones and a 10%+ royalty. However, such Phase I deals are infrequent and BioInvent investors need to be prepared to fund BI-505 to add value by generating Phase II efficacy data.
Into two at 10: BI-505 progression to Phase II
BI-505 blocks the function of the cell surface adhesion molecule ICAM-1 (CD54). In the cancer literature, myeloid cells show cell-adhesion mediated drug resistance if attached to other cells. In BioInvent’s patent EP 2468775 (priority December 2006), ICAM blocking is claimed to cause apoptosis (cell suicide). The 35-patient dose escalation study in relapsed and refractory MM tested 11 dose stages of 0.0004mg/kg to 20mg/kg. BI-505 at 10mg/kg saturated the ICAM sites on bone marrow myeloma cells; this dose will be used for Phase II. Stable disease (based on M protein biomarker levels) was seen in 24% of the 29 patients who received extended dosing over 0.06mg/kg (level 6). The likelihood of success remains at 30%.
Valuation: Cash conservation to rebuild the portfolio
BioInvent had Q3 ytd cash of SEK153m with revenues of SEK 34m. Estimating year-end 2012 cash is difficult due to the actual H212 restructuring costs; SEK25-40m seems a probable range. The company needs to invest in BI-505, bring forward two other candidates into Phase I and support n-CoDeR. Operating cash costs in 2013 should be SEK75m. The small Phase IIa BI-505 study due to start sometime in 2013 will be inexpensive; a broader Phase IIb may eventually follow. Collaborations may generate milestones in 2013 if partners designate clinical candidates. This could give funding into 2014 before any BI-505 deal value, if partnered in 2013.
To Read the Entire Report Please Click on the pdf File Below.
January 2013 brought a clear safety and dose signal in the BI-505 Phase I for relapsed and refractory multiple myeloma (MM). In preclinical studies, BI-505 showed a tumour cell killing effect possibly by making myeloma cells susceptible to apoptosis. The Phase I was dose escalating with a safety end point. Interestingly but anecdotally, seven of 29 patients (24%) on extended dosing showed stable disease. BI-505 will progress to a small Phase IIa during 2013. BioInvent (BINV.ST) intends to partner BI-505
The one: BI-505 is crucial to current value
BI-505 is the remaining clinical programme from the January 2012 portfolio. Hence, gaining maximum value is important for investors. A deal by GenMab in August 2012 with J&J on a Phase I MM antibody, daratumumab, shows possible value. GenMab, a larger company, gained $55m upfront and $88m in equity with milestones and a 10%+ royalty. However, such Phase I deals are infrequent and BioInvent investors need to be prepared to fund BI-505 to add value by generating Phase II efficacy data.
Into two at 10: BI-505 progression to Phase II
BI-505 blocks the function of the cell surface adhesion molecule ICAM-1 (CD54). In the cancer literature, myeloid cells show cell-adhesion mediated drug resistance if attached to other cells. In BioInvent’s patent EP 2468775 (priority December 2006), ICAM blocking is claimed to cause apoptosis (cell suicide). The 35-patient dose escalation study in relapsed and refractory MM tested 11 dose stages of 0.0004mg/kg to 20mg/kg. BI-505 at 10mg/kg saturated the ICAM sites on bone marrow myeloma cells; this dose will be used for Phase II. Stable disease (based on M protein biomarker levels) was seen in 24% of the 29 patients who received extended dosing over 0.06mg/kg (level 6). The likelihood of success remains at 30%.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
Valuation: Cash conservation to rebuild the portfolio
BioInvent had Q3 ytd cash of SEK153m with revenues of SEK 34m. Estimating year-end 2012 cash is difficult due to the actual H212 restructuring costs; SEK25-40m seems a probable range. The company needs to invest in BI-505, bring forward two other candidates into Phase I and support n-CoDeR. Operating cash costs in 2013 should be SEK75m. The small Phase IIa BI-505 study due to start sometime in 2013 will be inexpensive; a broader Phase IIb may eventually follow. Collaborations may generate milestones in 2013 if partners designate clinical candidates. This could give funding into 2014 before any BI-505 deal value, if partnered in 2013.
To Read the Entire Report Please Click on the pdf File Below.
Which stock should you buy in your very next trade?
AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?
Unlock ProPicks AI